Garfias-García S, Arroyo-Rodríguez S, Durán-del Rivero R

Language: Spanish
References: 23
Page: 188-194
PDF size: 85.78 Kb.

ABSTRACT

Bipolar disorder coexists with other psychiatric diagnoses and medical comorbidities. The objective of this case report and selective review of the literature is to divulge the comorbidity in bipolar disorder manic episode with psychotic features with a chronic hyperprolactinemic state. We report a female patient 30 years of age with galactorrhea of 6 years of evolution before the onset of any psychiatric treatment. During the study period had two manic episodes with psychotic features, requiring hospitalization on both occasions. Her symptoms subsided in 9 days with treatment with haloperidol and magnesium valproate. We discuss the treatment used and the indication of a second-generation antipsychotic effective in bipolar disorder profile and more appropriate to the circumstances of the case, including the finding of chronic hyperprolactinemia, which after ruled out as causes pituitary adenoma and hypothyroidism, was associated with other findings: polycystic ovaries. Finally, we analyze the probable participation of hyperprolactinemia as a trigger a manic episode.

REFERENCES

1. Krishnan KRR. Psychiatric and medical comorbidities of bipolar disorder. Psychosomatic Medicine 2005;67:1-8.

2. Schatzberg AF, Cole JO, DeBattista C. Manual of clinical psychopharmacology. 7th Ed. Washington, DC. Ame Psych Pub 2010;196-197;472;232-3.

3. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002;63:56-62.

4. Molitch ME. Medication-induced hiperprolactinemia. Mayo Clin Proc 2005;80(8):1050-7.

5. Nahas EAP, Nahás-Neto J, Pontes A, Dias R, Fernandes CE. Hyperprolactinemic conditions: relationships with psychiatric disorders. Rev Psiq Clín 2006;33(2):68-73.

6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.

7. DSM-IV-TR. Manual diagnóstico y estadístico de los trastornos mentales. 4ª Ed. Texto revisado. Barcelona. Masson 2002.

8. Tohen M, Bowden CL, Calabrese JR, Lin D, Forrester TD, Sachs GS, et al. Influence of sub-syndromal symptoms after remission from manic or mixed episodes. BJP 2006;189:515-9.

9. Figueroa R, Castano C. Episodio maníaco asociado al uso de sibutramina: Reporte de un nuevo caso. Rev Méd Chile 2008; 136:671-3.

10. Bowden CL. Valproate. En: Schatzberg AF, Nemeroff CB, Eds. Textbook of Psychopharmacology. 4th ed. Washington, DC. American Psychiatric Pub 2009;721-2.

11. Buckley PF, Foster AE. Quetiapine. En: Schatzberg AF, Nemeroff CB, Eds. Textbook of Psychopharmacology. 4th ed. Washington, DC. Am Psych Pub 2009;599-601.

12. Atmaca M, Kuloglu M, Tezcan E, Canatan H, Gecici O. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Archiv Med Resear 2002;33:562-5.

13. Hoffer ZF, Roth RL, Mathews M. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics 2009;50:317-24.

14. Joffe H, Hayes FJ. Menstrual cycle dysfunction associated with neurologic and psychiatric disorders. Their treatment in adolescents. Ann NY Acad Sci 2008;1135:219-29.

15. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hiperprolactinemia. CMAJ 2003;169(6):575-81.

16. Illa G. La prolactina y sus aplicaciones en psiconeuroinmunoendocrinología. Ed Polemos Buenos Aires, 2002.

17. Solís J, Cornejo P. Estados hiperprolactinémicos. Rev Med Hered 2006;17:234-45.

18. García-Rizo C, Fernández-Egea E, Oliveira C, Justicia A, Parellada E, Bernardo M, et al. Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. Schizophr Res 2011; doi:10.1016/j.schres.2011.07.025

19. Simpkins JW, Gabriel SM. Chronic hyperprolactinemia causes progressive changes in hypothalamic dopaminergic and noradrenergic neurons. Brain Research 1984;309:277-82.

20. Mohankumar PS, Mohankumar SMJ, Quadri SK, Voogt JL. Chronic hyperprolactinemia and changes in dopamine neurons. Brain Res Bull 1997;42(6):435-41.

21. Berns G, Nemeroff C. Neurobiology of bipolar disorder. Am JMed Gen 2003;123C:73-84.

22. Newberg AR, Catapano LA, Zarate CA, Manji HK. Neurobiology of bipolar disorder. Expert Rev Neurotherapeutics 2008; 8(1):93-110.

23. Tohen M, Chengappa KNR, Suppes T, Baker RW, Zarate CA,Bowden CL, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. BJP 2004;184:337-45.